Paper Details

  1. Home
  2. Paper Details

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

Author: ChooS P, GohB C, HartanoS, HuynhH, KohT S, LimC, LimK T, LowL S, NgQ S, TaiW M, ThamC K, ThngC H, TohH C, WangL Z, WangW W, YongW P

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This phase I study investigated the safety and efficacy of combining selumetinib with sorafenib in patients with advanced hepatocellular carcinoma (HCC). The study aimed to determine the maximum tolerated dose (MTD), assess safety and tolerability, and explore pharmacokinetics (PK) and biomarker correlates.
Paper Details　
Original Abstract of the Article :
Treatment with sorafenib, although associated with inhibition of tumour growth and angiogenesis in in vivo studies, leads to up-regulation of pERK. The addition of MEK inhibition could potentially abrogate this effect and potentiate anti-tumour activity. This phase I study investigated the maximum t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mdw415

データ提供：米国国立医学図書館（NLM）

Selumetinib and Sorafenib: A New Oasis in the Desert of Hepatocellular Carcinoma

The world of hepatocellular carcinoma (HCC) is a complex and challenging desert, with many obstacles to overcome. This study, a phase Ib trial, explores the potential for a combination of selumetinib and sorafenib as a new oasis of treatment options for individuals battling this form of liver cancer. The researchers, like skilled desert explorers, sought to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK), and biomarker correlates of this combination therapy. Their findings suggest that the combination could offer a potential therapeutic advantage, offering a new beacon of hope for those seeking effective treatments for HCC.

Navigating the Desert of HCC Treatment

This study offers a new path for navigating the desert of HCC treatment. The researchers' exploration of the combination of selumetinib and sorafenib provides valuable insights into the potential for this combination to improve treatment outcomes. Their findings highlight the importance of ongoing research and development to explore new and innovative treatment options for HCC.

A Glimpse of Hope in the Desert of Liver Cancer

The fight against liver cancer is a challenging journey. This study offers a glimmer of hope by exploring the potential of a combination of selumetinib and sorafenib as a new treatment option for HCC. While further research is needed, the study's findings suggest that this combination could offer a valuable tool in the fight against this devastating disease.

Dr.Camel's Conclusion

This study is like finding a hidden oasis in the vast desert of hepatocellular carcinoma (HCC) treatment. The combination of selumetinib and sorafenib offers a potential path toward improved outcomes for individuals battling this form of liver cancer. The researchers' findings remind us of the importance of ongoing research and exploration to uncover new and effective treatments for this challenging disease.

Date :
  1. Date Completed 2017-12-26
  2. Date Revised 2020-02-06
Further Info :

Pubmed ID

27681866

DOI: Digital Object Identifier

10.1093/annonc/mdw415

Related Literature

Article Analysis
・Side Effects of selumetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.